020 The combination of intratumoral delivery of inactivated modified vaccinia virus Ankara with systemic delivery of immune checkpoint blockade enhances antitumor immunity

Preclinical and clinical studies have shown that viral-based immunotherapy has the potential to overcome resistance to immune checkpoint blockade (ICB) and to fill the unmet needs of many cancer patients. Poxviruses, such as modified vaccinia virus Ankara (MVA), have the potential as cancer immunotherapeutic agents. We recently showed that intratumoral (IT) delivery of inactivated modified vaccinia virus Ankara (iMVA) induces antitumor systemic immunity via the STING-mediated cytosolic DNA-sensing pathway and Batf3 –dependent CD103+/CD8+ dendritic cells (DCs).
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Adaptive and Auto-Immunity Source Type: research